FastForward Innovations Limited Investee Company Update: Little Green Pharma Ltd
18 Febbraio 2021 - 10:37AM
RNS Non-Regulatory
TIDMFFWD
FastForward Innovations Limited
18 February 2021
FastForward Innovations Ltd / AIM: FFWD / Sector: Closed End
Investments
18 February 2021
FastForward Innovations Ltd
("FastForward", "FFWD" or the "Company")
Investee Company Update: Little Green Pharma Ltd
FastForward Innovations Ltd, the AIM quoted company focusing on
making investments in fast growing and industry leading businesses,
is pleased to note that Little Green Pharma Ltd ('LGP') has today
announced that it will be exclusively supplying medicinal cannabis
oil products to enrolled patients as well as providing funding for
study costs for the QUality of life Evaluation STudy ("The QUEST
Initiative"). The QUEST Initiative, which is being conducted by
researchers at the University of Sydney, aims to be one of the
world's largest longitudinal studies investigating the quality of
life and health economics on patients with chronic disease
prescribed medicinal cannabis. FastForward has a 0.9% interest in
the issued stock of LGP.
Ed McDermott, CEO of FastForward Innovations, commented: "Little
Green Pharma is one of our newest investments in the medical
cannabis space and we are delighted that it is already delivering
such strong newsflow. The QUEST Initiative aims to have at least
2,100 patients by 30 June 2021, which is a very significant number,
and it is excellent to hear that Little Green Pharma is involved
with the exclusive supply of medical cannabis oil products as well
as providing funding for study costs. We look forward to providing
updates as the study progresses."
The announcement is set out below without material changes or
adjustments other than for the inclusion of links and can be viewed
in full on LGP's website via the following link:
https://investor.littlegreenpharma.com/site/PDF/9f6a7d18-b9ad-4d67-b892-c630bf7f9727/LargeScaleCannabisStudyLaunched
LARGE SCALE CANNABIS STUDY LAUNCHED
18 FEBRUARY 2021
Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company")
wishes to advise of the media release issued today by the
University of Sydney relating to the QUality of life Evaluation
STudy ("The QUEST Initiative").
The QUEST Initiative aims to be one of the world's largest
longitudinal studies investigating the quality of life and health
economics on patients with chronic disease prescribed medicinal
cannabis.
LGP will exclusively supply medicinal cannabis oil products to
enrolled patients as well as providing funding for study costs.
The study, conducted by researchers at the University of Sydney,
is for a two-year period and aims to recruit at least 2,100
patients by 30 June 2021. It also has the potential to be extended
internationally.
Please see the Little Green Pharma announcement for details of
the study which can be found in an attached media release from the
University of Sydney.
ASX ANNOUNCEMENT LGP TO EXCLUSIVELY SUPPLY CANNABIS MEDICINES TO
WIDE-RANGING QUALITY OF LIFE STUDY ENDS FOR MORE INFORMATION,
PLEASE CONTACT:
Alistair Warren
Company Secretary
Little Green Pharma
E: alistair@lgpharma.com.au
M: +61 8 6280 0050
Fleta Solomon
Managing Director
Little Green Pharma
E: fleta@lgpharma.com.au
M: +41 782 260 200
About Little Green Pharma
Little Green Pharma is a vertically integrated medicinal
cannabis business with operations from cultivation and production
through to manufacturing and distribution.
The Company has an indoor cultivation facility and manufacturing
facility in Western Australia for the production of its own-branded
range of GMP-grade medicinal cannabis products.
Little Green Pharma products comply with all required
Therapeutic Goods Administration regulations and testing
requirements. With a growing range of products containing differing
ratios of active ingredients, Little Green Pharma supplies
medical-grade cannabis products to Australian and overseas
markets.
The Company has a strong focus on patient access in the emerging
global medicinal cannabis market and is actively engaged in
promoting education and outreach programs, as well as participating
in clinical investigations and research projects to develop
innovative new delivery systems.
For more information about Little Green Pharma go to:
www.littlegreenpharma.com
*** ENDS***
For further information on the Company please visit www.fstfwd.co or contact:
Ed McDermott / Lance FastForward Innovations Email: info@fstfwd.co
de Jersey Ltd
James Biddle / Roland Beaumont Cornish Tel: +44 (0) 207
Cornish Limited, 628 3396
Nomad
------------------------ -----------------------------------
Isabella Pierre / Damon Shard Capital Partners T: +44 (0)20 7186
Heath LLP 9927
------------------------ -----------------------------------
Isabel de Salis / Beth St Brides Partners Email: info@stbridespartners.co.uk
Melluish Ltd,
Financial PR
------------------------ -----------------------------------
Notes
FastForward Innovations is an AIM quoted investment company
focused primarily on disruptive high growth life sciences and
technology businesses particularly within the medical cannabis
arena. The Company's strategy is to identify early stage
opportunities that have an upcoming investment catalyst and grow
its portfolio in terms of value whilst limiting the number of
investee companies to a level where relevant time can be devoted to
each.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFZGMZLRDGMZG
(END) Dow Jones Newswires
February 18, 2021 04:37 ET (09:37 GMT)
Grafico Azioni Seed Innovations (LSE:SEED)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Seed Innovations (LSE:SEED)
Storico
Da Mag 2023 a Mag 2024